key: cord-0327545-vhk8hyhs
authors: Zhu, Keying; Wang, Yang; Sarlus, Heela; Geng, Keyi; Nutma, Erik; Sun, Jingxian; Kung, Shin-Yu; Bay, Cindy; Han, Jinming; Lund, Harald; Amor, Sandra; Wang, Jun; Zhang, Xingmei; Kutter, Claudia; Guerreiro Cacais, André Ortlieb; Högberg, Björn; Harris, Robert A.
title: Nanoengineered DNA origami with repurposed TOP1 inhibitors targeting myeloid cells for the mitigation of neuroinflammation
date: 2021-10-04
journal: bioRxiv
DOI: 10.1101/2021.10.04.462880
sha: 660c22c3d1b43d0d5cc9719bb7a29f72d1a42107
doc_id: 327545
cord_uid: vhk8hyhs

Targeting myeloid cells, especially microglia, for the treatment of neuroinflammatory diseases such as multiple sclerosis (MS), is underappreciated. Here, we screened a library of compounds and identified the topoisomerase 1 (TOP1) inhibitor camptothecin (CPT) as a promising drug candidate for microglial modulation. CPT and its FDA-approved analog topotecan (TPT) inhibited inflammatory responses in microglia and macrophages, and ameliorated neuroinflammation in mice. Transcriptomic analysis of sorted microglia revealed an altered transcriptional phenotype following TPT treatment, with Ikzf1 identified as a potential target. Importantly, TOP1 expression was found elevated in several neuroinflammatory conditions, including human MS brains. To achieve targeted delivery to myeloid cells we designed a nanosystem using DNA origami and loaded TPT into it (TopoGami). TopoGami also significantly suppressed the inflammatory response in microglia and mitigated disease progression in MS-like mice. Our findings suggest that TOP1 inhibition represents a therapeutic strategy for neuroinflammatory diseases, and the proposed nanosystem may foster future research and drug development with a demand to target myeloid cells.

Targeting myeloid cells, especially microglia, for the treatment of neuroinflammatory diseases 24 such as multiple sclerosis (MS), is underappreciated. Here, we screened a library of compounds 25 and identified the topoisomerase 1 (TOP1) inhibitor camptothecin (CPT) as a promising drug 26 candidate for microglial modulation. CPT and its FDA-approved analog topotecan (TPT) 27 inhibited inflammatory responses in microglia and macrophages, and ameliorated 28 neuroinflammation in mice. Transcriptomic analysis of sorted microglia revealed an altered 29 transcriptional phenotype following TPT treatment, with Ikzf1 identified as a potential target. 30 Importantly, TOP1 expression was found elevated in several neuroinflammatory conditions, 31 including human MS brains. To achieve targeted delivery to myeloid cells we designed a 32 nanosystem using DNA origami and loaded TPT into it (TopoGami). TopoGami also significantly 33 suppressed the inflammatory response in microglia and mitigated disease progression in MS-like 34 mice. Our findings suggest that TOP1 inhibition represents a therapeutic strategy for Introduction 38 The functions of the innate immune system are predominantly executed by cells of the myeloid 39 lineage ('myeloid cells'), which comprise monocytes, dendritic cells, macrophages, and 40 microglia. Myeloid cells play important roles in the regulation of inflammation, non-specific host 41 defense against microbes, the clearance of tissue debris, and the remodeling of tissues.

Emerging evidence has indicated a pivotal role of myeloid cells in the immunopathology of 48 neurological diseases. Infiltrating monocyte-derived macrophages destroy neurons and 49 oligodendrocytes during MS, and the action of pro-inflammatory microglia/macrophages drives 50 motor neuron death in ALS. A recent human genome-wide association study including 47,429 51 MS patients and 68,374 control cases determined that MS susceptibility genes were enriched in 52 microglia, but not in astrocytes or neurons, suggesting a potential but overlooked role of 53 microglia in MS susceptibility (1). The C9orf72 gene, whose dysregulation accounts for the most 54 frequent genetic cause of familial ALS, is highly expressed in myeloid cells (2). The absence of 55 C9orf72 in myeloid cells disturbs homeostasis and predisposes individuals to neuroinflammatory 56 disorders (3). A recent study also demonstrated that although peripheral myeloid cell infiltration 57 to the CNS was limited, macrophages along peripheral axons of motor neurons are activated in 58 ALS mouse models and ALS patients. Replacing them with less inflammatory macrophages 59 reduced the activation of microglia, delayed symptoms, and increased survival in ALS mice (4). 60 Myeloid cells therefore clearly represent a crucial therapeutic target for neuroinflammatory 61 diseases. 62 While endowed with high translational value and clinical demand, therapeutics developed to 63 specifically target myeloid cells are scarce. In this study, we designed a drug screening strategy 64 using Connectivity Map (CMAP) to identify drugs with the potential to modulate microglial 65 function. The topoisomerase 1 (TOP1) inhibitor camptothecin (CPT) emerged as a potent agent to 66 regulate microglial activation. We confirmed the beneficial effect of CPT and its FDA-approved 67 analog topotecan (TPT) on neuroinflammatory conditions and determined an increased TOP1 68 expression during neuroinflammation. Lastly, to achieve enhanced, specific delivery of TPT to 69 myeloid cells and to circumvent potential off-target effects on other immune cells, we loaded TPT 70 into a wireframe DNA origami structured in a hexagonal prism (5, 6), and surface-coated it with 71 β-glucan (herein referred to as TopoGami). The nanoengineered TopoGami significantly reduced 72 neuroinflammation in a similar fashion to TPT. Our findings indicate the FDA-approved drug 73 topotecan could be repurposed and translated for treating neuroinflammation, and the β-glucan-74 coated DNA origami system will be of great value for future drug development or studies using 75 demanding a specific targeting of myeloid cells. 79 To find suitable compounds that alter microglia states we used a repurposing approach by 80 utilizing a Connectivity Map (CMAP) discovery strategy (7), thus enabling a relatively quicker 81 translation of an existing approved drug to a new clinical application. We analyzed a dataset that 82 contains transcriptomic data from human microglia stimulated with defined stimulants to induce 83 different phenotypes: M1(LPS/IFNγ), M2a (IL-4/IL-13), M2c (-4/IL-13/IL-10), and Mtgfb (TGF-84 β) (Fig. 1a) . Although the nomenclature of M1/M2 microglial activation is now considered to be 85 an oversimplified dogma overlooking the heterogeneity and complexity of microglial activation 86 TOP1 inhibitors as potent drug candidates for SARS-CoV-2-induced lethal inflammation (8). 100 Therefore, we evaluated the possibility of repurposing TOP1 inhibitors to modulate 101 neuroinflammation. 103 We cultured primary microglia from adult mice and stimulated them with LPS/IFNγ (Fig. 2a) . We 104 observed an increased Top1 mRNA expression after 2 h stimulation, which gradually subsided 105 over time (Fig. 2b) . The intracellular/intranuclear regulation of TOP1 activity is not fully 106 elucidated, but some proteins have been proposed to regulate the recruitment of TOP1 to 107 chromatin or TOP1 degradation. Among these, BTB/POZ domain-containing protein 1 (BTBD1) 108 is known to specifically bind to TOP1, and may function as a TOP1 degradation regulator (9); the 109 DNA end-processing enzyme TDP1 counteracts the biological function of TOP1 cleavage 110 complexes (10); the serine/arginine-rich splicing factor 1 (SRSF1) inhibits the recruitment of 111 TOP1 from the nucleoplasm to the nucleolus (11). We observed a concomitant decrease in the 112 mRNA expression of these three negative regulators of TOP1 following microglial activation 113 (Fig. 2c) . We further confirmed an increased expression of TOP1 protein in microglia following 114 LPS/IFNγ stimulation by Western blotting and immunostaining (Fig. 2d-f, J), indicating an active 115 involvement of TOP1 during microglial activation. 116 To evaluate the anti-inflammatory effect of CPT we first investigated the cytotoxicity of CPT 117 on inflammatory microglia and a concentration below 1 μM showed no deleterious effect (Fig. 118 2g). We therefore used 1 μM CPT for subsequent experiments. Proinflammatory activated 119 microglia release cytotoxic molecules such as proinflammatory cytokines and produce nitric 120 oxide (NO) via the catalytic activity of inducible nitric oxide synthase (iNOS), which can damage 121 CNS neural tissue (12). CPT incubation significantly inhibited the release of NO from stimulated 122 microglia (Fig. 2h) , which was also confirmed by a decreased iNOS immunostaining (Fig. 2i, k) . 123 Following CPT incubation the mRNA expression of inflammatory genes Nos2, Tnfa, and Il1b 124 displayed a kinetic change; Il6 was inhibited by CPT at 1 h, but the kinetic expression pattern was 125 similar to that of the control group (Fig. 2p ). To our surprise, the mRNA expression of the anti-126 inflammatory cytokine IL-10, which is important for inflammation resolution and maintenance of 127 microglial homeostasis, was highly upregulated after 24 h in CPT-treated LPS/IFNγ-stimulated 128 microglia. 129 We then measured the cytokine release in the cell supernatant from activated microglia after 24 130 h. The production of TNF-α, IL-6, and the monocyte chemoattractant protein CCL2 was reduced 131 in CPT-treated microglia, whereas IL-10 production was increased (Fig. 2l-o ). An increased 132 intracellular TNF-α synthesis in stimulated microglia was also confirmed by cytokine staining 133 using flow cytometry, and CPT treatment also inhibited the synthesis of TNF-α (Fig. 2q,r) . Taken 134 together, TOP1 is upregulated upon microglial activation, and inhibiting TOP1 dampens 135 microglial inflammatory responses.

The FDA-approved TOP1 inhibitor topotecan ameliorates LPS-induced neuroinflammation 137 Given the effect of CPT on dampening microglia inflammatory responses in vitro, we next 138 assessed the effect of TOP1 inhibition in vivo. Due to the poor solubility of CPT, we used 139 topotecan (TPT), which is a water-soluble analog of CPT, for in vivo experiments. TPT was 140 approved by the FDA in 2007 for the treatment of small-cell lung cancer via oral administration. 141 Similar to CPT, TPT treatment also mitigated inflammatory responses in macrophages and 142 microglia in vitro (Extended Data Fig. 1 ). 143 We first employed the LPS challenge model, as it efficiently stimulates an innate immune 144 response characterized by the activation of myeloid cells. It has been reported that one systemic 145 LPS challenge induces robust microglial activation, depressive sickness behavior, and persistent 146 neuroinflammation, even when peripheral immune activation is tempered (13). We delivered 10 147 μL TPT (0.1 mg/kg) directly into the CNS via intracisternal injection, followed by 5 mg/kg (i.p) 148 LPS challenge, and analyzed the brain tissue after 4 h or 24 h (Fig. 3a) . The expression of Iba1, 149 whose immunoreactivity increases following microglial activation, was enhanced in different 150 brain regions upon LPS treatment, whereas TPT-treated mice exhibited a reduced Iba1 151 immunoreactivity ( Fig. 3b-d) . 152 Microglia rapidly adapt their morphology following activation. Resting microglia are ramified 153 cells with many intersections connecting a complex branching network, whereas activated 154 microglia retract their long processes and become amoeboid-like and less ramified (14). We (Fig. 3j,k) . TPT treatment also resulted in a general reduction of proinflammatory 161 cytokine levels compared to the LPS control group as evaluated by cytokine arrays of the brain 162 homogenates (Fig. 3l,m) . In addition, we also noted a better performance in an explorative 163 behavioral test following TPT treatment (Fig. 3n) , reflecting less depressive-like sickness. 164 Meanwhile, we also injected 10 ng of LPS directly into the CNS via intracisternal injection to 165 limit inflammation within the CNS and administered 1 mg/kg TPT (i.p). In this experimental 166 setting, we also observed an improved behavior following TPT treatment compared to the LPS 167 control group (Extended Data Fig. 2) . A previous study reported that CPT rescued mice from a 168 lethal LPS challenge (16). Similarly, we determined that a single low dose injection of TPT (1 169 mg/kg) could also prevent around 40% of mice from death induced by lethal inflammation (Fig. In addition to suppression of many inflammatory pathways following TPT treatment, 203 transcripts of oxidative phosphorylation, steroid biosynthesis, and mitochondrial respiratory 204 activities were enriched, indicating a potential metabolic reprogramming in microglia (Fig. 4e, h) . 205 We also predicted the potential transcription factors (TFs) mediating TPT effects by using we employed a treatment protocol comprising 3 injections of TPT (1 mg/kg; i.p) (Fig. 5a) . This is 226 a much lower dose (5 to 10-fold reduction) compared to previous studies using TPT as a typical 227 chemotherapeutic agent in rodent models and is equivalent to the well-tolerated dose reported in a 228 mouse model of Huntington's disease (25-27). We characterized that this treatment protocol did 229 not induce loss of body weight, nor a significant decrease in the number of peripheral immune 230 cells, excluding the unwanted immunosuppression and cytotoxic effects (Extended Data Fig. 4 ). 231 We included three TPT treatment groups with: (i) the pre-onset group receiving TPT on days 5, 232 7, and 9 post-immunization; (ii) the onset group receiving TPT on days 11, 13, and 15; and (iii) 233 the peak group on days 17, 19 and 21. EAE mice gradually lost weight upon disease onset, but 234 mice in the TPT pre-onset and onset treatment groups experienced less weight loss (Fig. 5b) . TPT 235 pre-onset treatment significantly delayed EAE disease onset and prevented some mice from 236 developing the disease ( Fig. 5c-g) . Both TPT pre-onset and onset treatment improved the EAE 237 clinical score (Fig. 5c ), while TPT treatment starting from disease peak failed to do so. We also 238 dissected the spinal cords at days 18 and 30 and confirmed a reduced infiltration of peripheral 239 monocytes into the spinal cord at EAE peak, and a smaller demyelinated area at EAE recovery 240 phase following TPT onset treatment ( Fig. 5i-m) . Furthermore, we analyzed the functionality of 241 the immune cells in the spinal cords at EAE peak from the TPT onset treatment group and PBS 242 control group. There was no difference in the frequency of Ki67+ CD4+ proliferating T cells, as 243 well as Foxp3+ CD4+ regulatory T cells (Extended Data Fig.5c,d) . In terms of cytokine 244 production, we did not observe a difference in GM-CSF and IFN-γ production of CD4+ T cells 245 between the two groups (Extended Data Fig.5e,f) , but we noted a significantly increased 246 production of IL-10 in CD11b+ myeloid cells in TPT-treated mice, while the difference in TNF-α 247 production was not significant (Extended Data Fig.5a,b) . Since the day-of-onset for each EAE 248 mouse varied even within the same EAE batch, we then treated the EAE mice individually from 249 the day the mouse was scored 1 for the first time, thereby ensuring that all mice were sick and at 250 an early onset phase when treatment commenced (Fig. 5h) . We again observed a significant (Fig. 6k) . In an MS cohort, the peri-lesion 271 normal-appearing white matter (NAWM) had higher TOP1 expression compared to the healthy 272 control white matter (Fig. 6m) . We further confirmed this by evaluating TOP1 expression in brain 273 tissues from MS patients, and in a like manner, a pronounced TOP1 expression in the lesion areas 274 as well as the NAWM, compared to the white matter from healthy control donors, was evident 275 (Fig. 6l) . In a sporadic ALS cohort, patients also showed increased TOP1 expression in the 276 anterior horn fraction (enriched for glial cells) compared to healthy controls, but this was not a 277 prominent feature in the neuronal fraction (Fig. 6n) . Taken together, these results indicate that 278 increased TOP1 expression is characteristic of several neuroinflammatory conditions and that 279 TOP1 is a potential target for controlling neuroinflammation. 280 Nanoengineered DNA origami for specific delivery of TPT to myeloid cells 281 Even though a low dose application of TPT had little toxicity, we aimed for more specific 282 delivery of TPT to myeloid cells. From a translational perspective, this would even enhance the 283 effect of TPT on myeloid cells, and meanwhile, minimize the potential off-target effects on other 284 cell types when applying TOP1 inhibition therapy in patients. 285 To specifically deliver TPT and to restrict its effect to myeloid cells, we took advantage of a 286 DNA origami system to load TPT and coated it with β-glucan, which is a ligand from baker's 287 yeast recognized mainly by the Dectin-1 receptor expressed on myeloid cells (28). The superiority 288 of using DNA origami as a drug delivery vehicle is its precision and reproducibility (29, 30). 289 Unlike other self-assembled nanoparticles that often have a relatively broad size distribution, 290 DNA origami has the same controlled shape, size, and charge for each particle. The DNA origami 291 nanostructure used in this work was a wireframe-stylized hexagonal rod (HR) with a length of 292 ~120 nm and a diameter of ~20 nm (Fig. 7a) . To coat the HR with β-glucan we designed 60 293 evenly distributed protruding single-stranded DNAs around the HR for the hybridization of These interactions between TPT and dsDNA thus enabled the loading of TPT into the DNA 301 origami nanostructure without chemical conjugation (Fig. 7a) . 302 We prepared the TPT-loaded and glucan-coated HR (HR-TPT-Glu) and denoted this system 303 'TopoGami'. We confirmed the expected hexagonal rod structure of TopoGami by transmission 304 electron microscopy (Fig. 7b) . Agarose gel electrophoresis of Cy5-labeled HR, TPT-HR, and 305 TopoGami revealed that all samples had sharp-structured bands, indicating the high quality and 306 consistency of structure production irrespective of TPT loading. More importantly, TopoGami 307 migrated poorly during electrophoresis, reflecting the fact that the structure was successfully 308 coated by glucan as it neutralized the negatively charged DNA (Fig. 7b,c) . We determined that 309 the saturated TPT loading capacity in 1 nM of HR was ~600 nM, and glucan coating had no effect 310 on the loading efficiency (Fig. 7d) . We also characterized the stability of the drug-loading DNA 311 origami structure by measuring the cumulative TPT release over time. The release profile of TPT 312 revealed no sudden increase within 84 h, indicating the stable integration between TPT and the 313 DNA nanostructure. When we added DNase, we observed that TPT release from TopoGami 314 accelerated gradually, whereas its release from the TPT-HR DNA origami without glucan coating 315 surged immediately (Fig. 7e ). This differential sensitivity to DNase thus suggested that β-glucan 316 coating, in addition to acting as a myeloid-binding ligand, can also protect the DNA nanostructure 317 from protein accessibility and prevent its degradation. 318 To confirm glucan-mediated internalization of the DNA structure, we incubated mouse primary 319 microglia with 2 nM HR or HR-Glu in both resting and activated states for 1 h. HR-Glu was 320 efficiently taken up by microglia compared to HR, irrespective of microglial activation state (Fig. 321 7f). This was further demonstrated by flow cytometry as an increased Cy5 fluorophore intensity 322 was observed in microglia treated with HR-Glu compared to those exposed to HR (Fig. 7g-i) . 323 We next assessed the interaction of glucan-coated HR to different immune cells using 324 splenocytes as a source. We separated the splenocytes into three major immune compartments 325 (myeloid cells, T cells, and B cells) and performed real-time structure-to-cell interaction assay 326 with each compartment (Fig. 7j) . All the three cell compartments had limited interactions with the 327 non-coated HR (Cy5-labelled), but the interaction between the Cy5-labelled HR-Glu and myeloid 328 cells was much higher than with B and T cells (Fig. 7k) . During the real-time measurement, HR-329 Glu had a faster association with myeloid cells (Fig. 7l) and a slight association with B cells (Fig. 330 7m) compared to HR; however, little association of HR-Glu was evident with T cells (Fig. 7n) . To 331 further validate these findings, we incubated splenocytes with Cy5-labelled HR-Glu and 332 performed flow cytometry (Fig. 7j) . We gated for the 3 cell types (Extended Data Fig. 7) and 333 again observed a significantly increased uptake of the HR-Glu DNA origami in the myeloid 334 compartment (Fig. 7o-q) . These results indicate that the glucan-coated HR DNA origami is a 335 reliable system to deliver TPT to myeloid cells. 336 TopoGami recapitulates the anti-inflammatory effects of TPT 337 We next verified the anti-inflammatory properties of TopoGami. We harvested the cells after 4 h 338 stimulation and performed RT-PCR analysis of inflammatory genes. Compared to the control 339 group, TopoGami strongly inhibited the mRNA expression of Nos2, Il1b, Il6, and Tnfa (Fig. 8a-340 d). We also analyzed cytokine release in the supernatants from treated cells after 24 h, and 341 TopoGami significantly inhibited the release of IL-6 and reduced TNF-α production to a large 342 extent (Fig. 8e,f) . To our surprise, we noted that HR-Glu itself also exhibited a certain degree of (16, 36) . Serendipitously, 366 we independently identified TOP1 inhibitors as potent anti-inflammatory agents for inflammatory 367 microglia and demonstrated their efficacy in treating neuroinflammatory diseases. Importantly, 368 we designed a novel nanoengineered TOP1 inhibitor (TopoGami) that could efficiently and 369 specifically target myeloid cells and reduce their proinflammatory activation state. 370 We screened a list of compounds with underlying microglia-modulating function using 371 Connectivity Map. Apart from camptothecin, the high rank of mitoxantrone on the list is also 372 noteworthy. Mitoxantrone was originally developed as an antineoplastic drug but was repurposed 373 and approved for use in relapsing-remitting MS and aggressive progressive MS (37, 38) . 374 Although the mechanism of mitoxantrone in treating MS was not fully elucidated when it was (51, 52) . Therefore, the role of Ikaros in macrophages and 431 microglia is controversial and not fully understood. We identified Ikaros as a potential 432 downstream target of TPT, but this needs more investigations in the future. 433 TPT treatment initiated at the peak of EAE failed to ameliorate clinical neurological signs of 434 EAE. We consider that during the EAE recovery phase the infiltration of immune cells and 435 progressive inflammation has retarded, while oligodendrocyte precursors proliferate at a high 436 pace and differentiate into mature oligodendrocytes to repair demyelinated nerves. TPT treatment 437 during this phase is not effective in this less inflammatory context but may affect cell proliferation 438 and subsequent remyelination (53). Coincidentally, a very recent study using a network-based 439 deep learning algorithm developed for novel drug target identification and in silico drug 440 repurposing also predicted that TPT is an effective inhibitor of RORγt and thus, may cure EAE 441 (54). In this study, they treated EAE mice from disease onset with TPT using a relatively high 442 dose (10 mg/kg; i.p) and observed a protective effect. However, since TPT is a chemotherapeutic 443 drug, with this high dose it is hard to distinguish if the effect is simply due to an overall 444 immunosuppression/cytotoxicity on the highly proliferating immune cells. In our study, we used a 445 much lower dose (1 mg/kg; i.p) and confirmed that our treatment regime did not induce 446 cytotoxicity in naive mice. Furthermore, we also proved that inhibiting TOP1 only in CNS production in activated microglia to a certain degree, but the effect of TopoGami was far superior. 471 We speculate that the nanostructure may have some sequences that act like NF-κB decoy oligos, Table S2 . 575 Nitric oxide detection and cytokine analysis 576 The measurement of nitric oxide (NO) in the supernatants was performed using the modified 577 Griess reagent (Sigma, G4410). Samples (100 μL) were plated in a flat 96-well plate (Corning), 578 and mixed with equal volumes of freshly prepared Griess reagent, and incubated for 15 min at 579 room temperature. The plate was read at 540 nm using a microplate reader (LabSystems). The 580 cytokine release to the supernatants was measured using BD™ Cytometric Bead Array (CBA) 581 following the manufacturer's protocol and detected using a BD FACSVerse flow cytometer. The Statistical analyses were performed with Graphpad Prism 8, and a P value less than 0.05 was 678 considered significant. In general, data were presented as group means ± s.e.m. The Student's 679 unpaired two-tailed t-test was used to compare the difference when two groups were compared, 680 and one-way ANOVA with Dunnett's Multiple Comparison test for comparison for more than 681 two groups. For EAE score-based analyses (average, cumulative, and max EAE score), the 682 Kruskal-Wallis test with Dunn's multiple-comparisons test was used when more than 2 groups 683 were compared, and the Mann-Whitney U test was used to compare between two groups. The 

Multiple Sclerosis Genetics Consortium, Multiple sclerosis genomic map 691 implicates peripheral immune cells and microglia in susceptibility

C9orf72 is required for 696 proper macrophage and microglial function in mice

C9orf72 in myeloid cells suppresses STING-induced 700 inflammation

Modifying 703 macrophages at the periphery has the capacity to change microglial reactivity and to extend 704 ALS survival

DNA 706 rendering of polyhedral meshes at the nanoscale

DNA Origami Penetration in Cell Spheroid Tissue Models is Enhanced by Wireframe 709

The Connectivity 713 Map: using gene-expression signatures to connect small molecules, genes, and disease

Topoisomerase 1 inhibition therapy protects against SARS-CoV-2-induced inflammation and 724 death in animal models

Chromatin 726 remodeller SMARCA4 recruits topoisomerase 1 and suppresses transcription-associated 727 genomic instability

Tdp1 protects from 729 topoisomerase 1-mediated chromosomal breaks in adult zebrafish but is dispensable during 730 larval development

Effects of SRSF1 on subnuclear localization of 732 topoisomerase I

Iron-sulfur glutaredoxin 2 protects oligodendrocytes against damage 736 induced by nitric oxide release from activated microglia

Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration

Microglia Morphological Categorization in a Rat Model of 742

Topoisomerase 1 inhibition suppresses inflammatory 750 genes and protects from death by inflammation

Hijacking of the AP-1 Signaling 752 Pathway during Development of ATL

JUNB/AP-1 controls IFN-γ during inflammatory liver disease

CCAAT/enhancer binding protein delta in microglial activation

Biological roles of CCAAT/Enhancer-binding protein 761 delta during inflammation

Epigenetic regulation of gene expression by Ikaros

Kinase II in leukemia

Ikaros expression in tongue sole macrophages: a marker for 766 lipopolysaccharide-and lipoteichoic acid-induced inflammatory responses

Inhibition of histone deacetylase 1 or 2 reduces induced 769 cytokine expression in microglia through a protein synthesis independent mechanism

Experimental autoimmune 772 encephalomyelitis (EAE) as a model for multiple sclerosis (MS)

Clinical relevance of human cancer xenografts as a 776 tool for preclinical assessment: example of in-vivo evaluation of topotecan-based 777 chemotherapy in a panel of human small-cell lung cancer xenografts

Optimization of liposomal topotecan for use in treating neuroblastoma

Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of 784

Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic 787 inflammation

A logic-gated nanorobot for targeted transport of 789 molecular payloads

Folding DNA to create nanoscale shapes and patterns

schizophyllan/poly(dA) triple-helical complex in dilute solution

Polysaccharides as Novel One-Dimensional Hosts for DNA/RNA, Conjugated Polymers and 797

Binding of topotecan to a nicked DNA oligomer in solution

The 802 mechanism of topoisomerase I poisoning by a camptothecin analog

Unraveling the mode of binding of the 805 anticancer drug topotecan with dsDNA

TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation

Mitoxantrone in relapsing-remitting and rapidly 809 progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone

Mitoxantrone in 813 progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre 814 trial

Mitoxantrone, pixantrone and 817 mitoxantrone (2-hydroxyethyl)piperazine are toll-like receptor 4 antagonists, inhibit NF-κB 818 activation, and decrease TNF-alpha secretion in primary microglia

Lipopolysaccharide enters the rat brain by a lipoprotein-mediated transport 822 mechanism in physiological conditions

Lipopolysaccharide-induced 825 blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, 826 and elements of the neurovascular unit

The Th17 immune response is controlled by the Rel-RORγ-RORγT 875 transcriptional axis

An updated histological 877 classification system for multiple sclerosis lesions

Oligolysine-based coating protects 880 DNA nanostructures from low-salt denaturation and nuclease degradation

One-Step Formation of "Chain-Armor"-Stabilized DNA Nanostructures

Cationic polymers for DNA origami coating -examining their 887 binding efficiency and tuning the enzymatic reaction rates

Anti-890 inflammatory and Antioxidative Effects of Tetrahedral DNA Nanostructures via the 891 Modulation of Macrophage Responses

Adoptive transfer of cytokine-induced 897 immunomodulatory adult microglia attenuates experimental autoimmune encephalomyelitis 898 in DBA/1 mice

Elevated levels of placental 901 growth factor represent an adaptive host response in sepsis

Lipopolysaccharide affects exploratory behaviors toward novel objects by impairing 905 cognition and/or motivation in mice: Possible role of activation of the central amygdala

Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, 909 sickness behavior, and anhedonia

Microglial autophagy-associated phagocytosis is essential for recovery from 913 neuroinflammation

Single-step purification and refolding of recombinant 915 mouse and human myelin oligodendrocyte glycoprotein and induction of EAE in mice

Cytokine gene delivery into the central 918 nervous system using intrathecally injected nonreplicative viral vectors

Trimmomatic: a flexible trimmer for Illumina sequence 921 data

Salmon provides fast and bias-923 aware quantification of transcript expression

Differential analyses for RNA-seq: transcript-level 925 estimates improve gene-level inferences

Bioconductor package for 927 differential expression analysis of digital gene expression data

clusterProfiler: an R Package for Comparing 930

Biological Themes Among Gene Clusters

BART: a 933 transcription factor prediction tool with query gene sets or epigenomic profiles

Simple Combinations of Lineage-Determining Transcription Factors 937

Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities. Molecular 938 Cell

Diagnostic criteria for multiple sclerosis: 2005 revisions to 942 the "McDonald Criteria

Staging of multiple sclerosis (MS) lesions: pathology of the 944 time frame of MS

Alzheimer's 947

the other drug candidates, camptothecin has the highest overall correlation to 1017 induce all these 6 patterns. 1018 primary microglia. a, A schematic overview of the in vitro experiments

Kinetic change of mRNA expression of Top1, Btbd1, Tdp1, and Srsf1 in microglia 1022 following LPS/IFNγ stimulation (n = 6). d, e, The protein expression of TOP1 was 1023 detected by Western blotting

IFNγ 1025 stimulation) or resting microglia, co-stained with Hoechst (blue) (bar = 20 μm); for 1026 the lower-left panel in (j), n = 3 per group (2 to 5 random fields per well were 1027 analyzed); for the lower right panel, 201 cells from unstimulated microglia and 256 1028 cells from stimulated microglia were analyzed. g, Cytotoxicity of CPT on 1029 stimulated microglia was determined by measuring the release of LDH in the 1030 supernatants (n = 4). h, Supernatants were collected after 24 h LPS/IFNγ 1031 stimulation and measured for nitrite, as an index of nitric oxide (NO) production (n 1032 = 4)

Immunostaining of iNOS (red) and Phalloidin (green) in microglia (n = 3 with 1034 more than 5 random fields per well) (bar = 50 μm). l-o

IL-10) to the supernatants were measured by cytometric beads 1036 assay after 24 h LPS/IFNγ stimulation (n = 4). The graphs show representative 1037 results of three independent experiments. p, The kinetics of mRNA expression of 1038

Il1b, Il6, and Il10 after 1, 3, 6, and 24 h of LPS/IFNγ stimulation (n = 3 1039 to 6). The graphs show representative results of three independent experiments

The graphs are representative of two independent experiments. Data 1042 shown are mean ± s.e.m. *P<0.05, **P<0.01, ***P<0.001. Statistical analyses 1043 were performed using two-way ANOVA with Dunnett's Multiple Comparison test 1044 for b and c, Student's unpaired two-tailed t-test for e and j, and one-way ANOVA 1045

Topotecan (TPT) mitigates microglial activation and CNS inflammation in 1048

An overview of the experimental design. b, Microglia in 1049 hippocampus and thalamus were stained with Iba1 (red). c, d, Fluorescent intensity 1050 of Iba1 in hippocampus and thalamus; n = 2, 4, 5 mice for naive, LPS, and LPS + 1051 TPT group

1052 representative of two independent experiments. e-i, Sholl analysis was performed 1053 to analyze the morphology of microglia. Microglia marked in yellow boxes in (b) 1054 were presented accordingly in (e); the morphological changes of microglia were length (h), and the ramification index

1058 to 7 complete microglia from each mouse were included for analysis). j, k, 1059 Expression of inflammatory genes in the hippocampus and hypothalamus 4 h after 1060 the LPS challenge (n = 3); data are representative of two independent experiments 1061 with similar results. l, m, Cytokine array on brain homogenates after 24 h of LPS 1062 challenge (n = 2 for naive, n = 3 for LPS and LPS + TPT group). n, The contact 1063 frequency of each mouse to the new toy during the cage explorative experiment 1064 was recorded in a 5-min recording (n = 5, 12, 13 mice for naive, LPS_PBS, and 1065 LPS_TPT group, respectively)

LPS + TPT group received 1 mg/kg TPT 1 h before the lethal dose LPS 1068 challenge, whereas the control group received PBS injection (n = 14). Data shown 1069 are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. Statistical analyses 1070 comparing the LPS_PBS group with the LPS_TPT group were performed using

Student's unpaired two-tailed t-test; the survival curve was analyzed with Log-1072 rank

Multidimensional scaling (MDS) analysis of brain microglia sorted 1076 from the following groups (n = 3): naive group (mice received i.p injection of PBS 1077 and intracisternal injection of PBS), LPS group (mice received i.p injection of 5 1078 mg/kg LPS following intracisternal injection of PBS), and TPT group (mice 1079 received i.p injection of 5 mg/kg LPS following intracisternal injection of 0.1 1080 mg/kg TPT); numbers labelled between different clusters indicate the number of 1081 differentially expressed genes (DEGs) identified by EdgeR (FDR=<0.05). b, 1082 Volcano plot depicting the DEGs between the TPT and LPS groups

GSEA plot of the enriched KEGG pathways related to 1087 inflammation between the TPT and LPS groups. e, h, Dot plots showing the top10 1088 suppressed and activated GO terms (e) or KEGG pathways (h) between the TPT 1089 and LPS groups. f, g, Heatmaps plotting the changes in expression levels of genes 1090 contributing to the enrichment analysis of TNF signaling pathway (f) and NF-κB 1091 signaling pathway (g) across samples when comparing the TPT group with the LPS 1092 group

TF) 1094 predicted to regulate the gene expression between the TPT and LPS groups. j, The 1095 Scatter plot shows the Irwin-Hall and FDR value of the 8 genes in (i); FDR was 1096 obtained from differential expression (DE) analysis; Irwin-Hall P-value was 1097 obtained from BART prediction, indicating the integrative ranking significance; the 1098 color gradient indicates FC in DE analysis. k, BART output of association score 1099 cumulative distribution of Ikzf1. l, BART output of transcriptional regulator 1100 prediction rank of Ikzf1. m, De novo motif

onset group (day 11, 13, 15), and peak group (day 17, 19, 21); mice in 1106 the EAE control group received 3 PBS injections randomly from day 5 (i.p). b, the groups were analyzed using different parameters: area under the curve (c), day 1109 of onset (d)

11 per group; data are from one EAE batch representing three batches 1111 with a similar effect. h, EAE mice were treated individually from the day when 1112 they were just scored or scored higher than 1; n = 8 mice per group. Data were 1113 representative of two independent batches. i, EAE mice received TPT treatment 1114 from the onset or PBS were euthanized at the peak of EAE (day 18), and the spinal 1115 cords were dissected for flow cytometry with an antibody panel for myeloid cells 1116

macrophages (Mac), microglia (Mic) and neutrophils (Neutro), were graphed in (j)

Fluoromyelin 1120 (green), and Hoechst (blue) (bar = 100 μm); the CD11b immunofluorescent 1121 intensity was graphed in (l), and the percentage of demyelinated area in the white 1122 matter of the spinal cord was graphed in (m)

The following statistical analyses were 1124 used: the EAE scores in (d-g) were analyzed using the Kruskal-Wallis 1125 nonparametric test; the AUC in (c) was analyzed using the one-way ANOVA with 1126

Multiple Comparison test, and the Student's unpaired two-tailed t-test 1127 was used for comparing the EAE-PBS group with the EAE-TPT group in h, j, l, 1128 and m

TOP1 expression is increased in neuroinflammatory conditions. a, Expression 1131 of TOP1 was examined in the LPS and EAE mouse models, and MS brain sections

Microglia 1133 were sorted from LPS challenged mice (i.p) after 4 h or naive mice, and the mRNA 1134 expression of TOP1 was graphed (n = 5 or 6); the experiments were performed twice. c, d, Western blotting of TOP1 expression from brain homogenates of mice 1136 receiving intracisternal LPS injection or PBS after 8 h (n = 4); graphs are 1137 representative of two experiments. e-g, Immunofluorescent staining of spinal cord 1138 sections from mice at EAE peak and control mice with anti-F4/80 (green), TOP1 1139 (magenta), and nuclei with Hoechst (blue); a magnified image of the selected 1140 region in (e) is shown in (f) and the mean fluorescent

sections from 1142 each mouse; bar = 200 μm; the yellow arrow indicates a representative F4/80+ cell 1143 with increased TOP1 expression in the nucleus. h, TOP1 expression in the spinal 1144 cord homogenates of EAE mice dissected at disease peak (scored 3) or control 1145 mice was examined by Western blotting, and quantified in (i) with normalization to 1146 GAPDH and β-actin (n = 3). j, TOP1 expression in healthy adult human CNS cells 1147 was extracted from the Brain Myeloid Landscape

Brain sections from healthy control and MS brain tissues, including the active MS 1150 lesion, chronic active lesion, and the normal-appearing white matter (NAWM), 1151 were stained with anti-HLA-DR, anti-TOP1, and co-stained with Hoechst (bar = 50 1152 μm). m, n, Data mining on TOP1 expression from GSE108000 (an MS cohort 1153 containing NAWM from 15 MS cases, and white matter from 10 healthy controls) 1154 and GSE18920 (an ALS cohort containing gene expression data from neuronal 1155 fraction and anterior horn fraction of 8 healthy donors and 12 sporadic ALS 1156 patients)

The student's unpaired two-tailed t-test was performed for statistical 1158 analyses except (k), which was performed using two-way ANOVA

Multiple Comparison Test. ### Padj ≤ 1e-04 when comparing microglia with other 1160 cell types, according to the analysis from the Brain Myeloid Landscape 2

A bioengineered DNA-origami nanosystem for selective topotecan (TPT) 1163 delivery to myeloid cells. a, TPT was loaded into the hexagonal rod

electrophoresis on 2% agarose gel; the gel is pre-stained with ethidium bromide 1168 and imaged under the UV channel and Cy5 channel. d, TPT loading efficacy of HR 1169 and glucan-coated HR. e, Cumulative TPT release profiles of TPT-HR and labeled HR or HR-Glu structures (in magenta) by non-stimulated or stimulated 1172 mouse primary microglia (in cyan) after 1 h incubation with 2 nM of the structures 1173 (bar = 20 μm); the experiment was performed twice. g-i, Flow cytometry analysis 1174 comparing the uptake of Cy5-labeled HR or HR-Glu structures in non-stimulated 1175 microglia incubated with 2 nM of the structures for 1 h (n = 3); the quantification 1176 was based on the median fluorescent intensity (MFI) or the percentage of Cy5-1177 expressing cells in total cells; data are representative of two independent 1178 experiments. j, Splenocytes were processed for comparing the uptake of Cy5-1179 labeled HR-Glu structure in different immune cells. The cells were separated using 1180 magnetic-activated cell sorting (MACS) into 3 compartments (myeloid cells, T 1181 cells, and B cells) for subsequent LigandTracer experiments in (k-n), or directly 1182 incubated with Cy5-labeled Glu-HR for flow cytometry analysis (o-q). k, The 1183 fluorescent signal of Cy5 in different immune cell compartments after 8 h 1184 incubation with HR or HR-Glu in LigandTracer experiments; T for T cells, B for B 1185 cells, and M for myeloid cells; data are pooled from three observations. l, m, The 1186 real-time interaction of Cy5-labeled HR or HR-Glu structures to myeloid cells, B 1187 cells, and T cells

cells; the 1192 quantification was based on the median fluorescent intensity (MFI) or the 1193 percentage of Cy5-expressing cells in each population (n = 3); the experiment was 1194 repeated twice with similar results

The statistical analysis was performed using One-1196 way ANOVA with Dunnett's Multiple Comparisons Test

The mRNA expression of Nos2, Il1b, Il6, and Tnfa in 1200 microglia treated with HR

The cytokine release of IL-6 and TNF-α from microglia treated with HR

or TopoGami after 24 h LPS/IFNγ stimulation were measured by 1204 cytometric beads assay (n = 4); the experiment has been repeated twice. g, h, Mice 1205 with EAE received intracisternal injections of TopoGami, HR-Glu, or PBS

Glu groups); data are pooled from two independent EAE 1208 batches

The comparison between the TopoGami group and control group

a-f) was performed using the Student's unpaired 1211 two-tailed t-test; the analysis of the AUC in (g) was analyzed using one-way 1212 ANOVA with Dunnett's Multiple Comparison test

Topotecan (TPT) inhibits inflammatory responses in microglia 1215 and macrophages. a, mRNA expression of Nos2, Il6, Tnfa, Il1b, Il10 and Arg1 in 1216 microglia after 2 h LPS/IFNγ stimulation incubated with 1 μM TPT or control 1217 (PBS). n = 3 per group

Nitric oxide release from microglia treated with 1 μm TPT or control under

LPS/IFNγ stimulation after 24 h. n = 4 per group; naive resting microglia were 1220 included as a negative control. c, The cytokine release of IL-6 and TNF-α from 1221 stimulated microglia treated with 1 μm TPT or control was measured using

Il10 and Arg1 in macrophages after 24 h LPS/IFNγ stimulation incubated with

Extended Data Fig. 2 Cage explorative behavior of mice receiving LPS injection via 1228 intracisternal routine. 10 ng of LPS was injected directly into the CNS via 1229 intracisternal injection and 1 mg/kg TPT (or PBS) was administered 1230 intraperitoneally. The frequency of toy contacts (a), rearing (b) and total activities 1231 (toy contact + rearing) (c) was recorded during the following 48 h. n = 9 for PBS 1232 and TPT group

the DEGs between the LPS and naïve groups. Dots represent non-DEGs (grey) and

Bubble 1239 plots showing the top10 enriched suppressed/activated GO terms (b) as well as 1240 KEGG pathways (c) between the LPS and naïve groups. d, GSEA plot of the 1241 enriched KEGG pathways related to inflammation between the LPS and naïve 1242 groups. e, Category net plot of top5 enriched KEGG pathways when comparing the 1243 TPT group with the LPS group. The color gradient indicates the fold changes 1244 between the TPT and LPS groups computed by EdgeR (log2 transformed); the size 1245 of the category (pathways enriched) indicates the number of genes contributing to 1246 the enrichment. f-h Heatmaps plotting the changes in expression levels of the genes 1247 contributing to the enrichment analysis of MAPK signaling pathway (f), Toll-like 1248 receptor signaling pathway (g) and IL-17 signaling pathway

Fig. 4i according to BART result; Irwin-Hall P-value indicates the integrative rank 1251 significance; color gradients were coded by BART-computed relative rank. j, Bar 1252 plot of the de novo motifs enriched at the promoters of DEGs between the TPT and 1253 LPS groups

Extended Data Fig. 4 The effect of TPT treatment on the peripheral immune cell 1274 components under physiological conditions. a, The body weight change 1275 following 3 times TPT injection

CSF (e) and IFN-γ (b) in the CD4+ T cells; the frequency of GM-CSF-producing 1287 and IFN-γ-producing CD11b+ cells were graphed. *P < 0.05 using Student's 1288 unpaired two-tailed t-test

Gene 1291 expression data from the dataset GSE97930 was extracted from the Brain Myeloid 1292

## Padj ≤ 0.001 when comparing myeloid cells with other cell types, 1293 according to the analysis from the Brain Myeloid Landscape 2

Extended Data Fig. 7 Flow cytometry gating strategy of the splenocytes

 950 We thank Tojo James for converting the gene symbols to the Affymetrix HG-U133A 951 probe identifiers. We thank Eliane Piket for introducing the techniques for intracisternal 952 injection. We thank Sebastian Lewandowski for providing insights about ALS and related 953 scientific discussions. We appreciate Feng Yang's advice on the artwork design. We are